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a  b  s  t  r  a  c  t
Bronchiolitis  obliterans  (BO)  is  a rare  disease  involving  concentric  bronchiolar  ﬁbrosis  that  develops
rapidly  following  inhalation  of  certain  irritant  gases  at sufﬁciently  high  acute  doses.  While  there  are
many  potential  causes  of bronchiolar  lesions  involved  in a  variety  of  chronic  lung  diseases,  failure  to
clearly  deﬁne  the clinical  features  and  pathological  characteristics  can lead to ambiguous  diagnoses.  Irri-
tant  gases  known  to cause  BO follow  a similar  pathologic  process  and  time  course  of  disease  onset  in
humans.  Studies  of inhaled  irritant  gases  known  to cause  BO  (e.g.,  chlorine,  hydrochloric  acid,  ammonia,
nitrogen  oxides,  sulfur  oxides,  sulfur  or nitrogen  mustards,  and  phosgene)  indicate  that  the  time  course
between  causal  chemical  exposures  and  development  of clinically  signiﬁcant  BO disease  is typically  lim-
ited to  a  few  months.  The  mechanism  of  toxic  action  exerted  by  these  irritant  gases  generally  involves
widespread  and  severe  injury  of the  epithelial  lining  of the  bronchioles  that leads  to acute respiratory
symptoms  which  can  include  lung  edema  within  days.  Repeated  exposures  to  inhaled  irritant  gases  at
concentrations  insufﬁcient  to  cause  marked  respiratory  distress  or edema  may  lead  to adaptive  responses
that  can reduce  or prevent  severe  bronchiolar  ﬁbrotic  changes.  Risk  of  BO from  irritant  gases  is  driven
substantially  by toxicokinetics  affecting  concentrations  occurring  at the  bronchiolar  epithelium.  Highly
soluble  irritant  gases  that  cause  BO like  ammonia  generally  follow  a threshold-dependent  cytotoxic  mech-
anism  of  action  that  at sufﬁciently  high  doses  results  in severe  inﬂammation  of  the  upper  respiratory  tract
and the  bronchiolar  epithelium  concurrently.  This  is  followed  by acute  respiratory  distress,  pulmonary
edema,  and  post  inﬂammatory  concentric  ﬁbrosis  that become  clinically  obvious  within  a few  months.
In contrast,  irritant  gases  with  lower  solubility  like  phosgene  also  follow  a threshold-dependent  mech-
anism  of cytotoxicity  action  but can  exhibit  more  insidious  and isolated  bronchiolar  tissue  damage  with
a  similar  latency  to  ﬁbrosis.  To  date,  animal  and  human  studies  on the highly  soluble  gas,  diacetyl,  have
not  identiﬁed  a coherent  pattern  of pathology  and  latency  that would  be expected  based  on  studies  of
other  known  causes  of bronchiolitis  obliterans  disease.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Generally accepted diagnostic criteria for bronchiolitis obliterans disease.
1. Pulmonary function tests show clinically important ﬁxed obstructive
deﬁcits indicating small airways disease without appreciable impacts on
total  lung volume and gas exchange measurements.
2.  The obstructive changes are resilient to treatment by corticosteroids or
bronchodilators.
3.  The patient’s lungs show a mosaic pattern of attenuation on high resolution
computed tomography (HRCT) scans indicating air trapping, especially
during exhalation.
4. Lung biopsy shows deﬁnitive histopathology of widespread and severe
concentric ﬁbrosis of the bronchioles.References.  .  . . . .  . . . .  . . .  . . . .  .  . . . .  . . . . . .  . . .  .  . . .  .  . . .  .  .  . .  .  . . .  . . . .  . . . . . . .  .  . 
. Clinical deﬁnitions of ﬁxed obstructive lung disease and
ronchiolitis obliterans disease
Obstructive lung disease is “characterized by an increase in
esistance to airﬂow owing to partial or complete obstruction at
ny level from the trachea and larger bronchi to the terminal and
espiratory bronchioles” [50]. In contrast, restrictive lung disease
s caused by the “reduced expansion of lung parenchyma, with
ecreased total lung capacity” [50]. The major types of obstruc-
ive disorders are emphysema, chronic bronchitis, bronchiectasis,
nd asthma [50]. Several bronchiolitis diseases, including bronchi-
litis obliterans (BO), are also considered obstructive lung diseases
50,73]. Each of these clinical disease entities, and a variety of more
peciﬁc conditions, can occur in the same individual but each can
iffer greatly with respect to pathology, functional consequences,
edical treatments, and known or suspected risk factors. In par-
icular, there are several disease states and exposures that can
ead to obstructive bronchiolar lesions and/or obstructive bronchi-
litis obliterans (BO) disease, so attribution of BO disease to one
articular exposure or risk factor may  be scientiﬁcally tenuous.
dditionally, diagnosis of BO disease is hampered by its similarity
o other obstructive bronchiolitis conditions [73].
It should be noted that the terminology ‘bronchiolitis obliter-
ns syndrome’ (BOS) was originally used to describe bronchiolar
brosis occurring as a common element of tissue rejection and/or
nfectious insults in lung transplant patients who  undergo phar-
aceutical therapy to avoid tissue rejection [40]. In such cases, the
ewly implanted lungs may  be diagnosed with BOS assumed to
e caused by the complex interactions of the individual’s immune
ystem and hence lung biopsies are not considered necessary for
iagnosis of BOS. Some authors of occupational investigations of
ung disease have borrowed the BOS terminology to apply to
iacetyl- or ﬂavoring-related lung disease (e.g., [2,94]). However,
uch use of this terminology could be a misnomer in that, based
n currently available information, no similar conditions (e.g., in
erms of causal agents or risk factors) apply for BOS in lung trans-
lant patients as distinguished from BO disease potentially related
o occupational chemical exposures.
Fixed airway obstruction is a nonspeciﬁc and relatively com-
on  lung condition in people over the age of 50 with varied
egrees of breathing difﬁculties that are not reversible with med-
cations, e.g., bronchodilators for asthma or steroid treatment for
cute lung inﬂammation [50]. Fixed airway obstruction, including
O disease, is a subset of conditions under the general cate-
ory of chronic obstructive pulmonary disease or COPD [50].
bstructive lung diseases and associated bronchiolar lesions may
lso occur in combination with or as a later consequence of
estrictive lung changes, such as various diffuse interstitial lung
iseases: pulmonary ﬁbrosis, respiratory bronchiolitis, respiratory
ronchiolitis-associated interstitial lung disease, hypersensitiv-
ty pneumonitis, collagen vascular diseases, and various types of
neumonia, including bronchiolitis obliterans organizing pneu-
onia (BOOP) and pneumoconioses (dust-related lung diseases)
50,52]. Bronchiolitis lesions can be found in association with these
bstructive and restrictive clinical conditions, with overlapping
maging and histopathological features [17,73]. Although bronchi-
lar lesions represent permanent damage to the lung architecture,
he vast number of small airways and excess oxygenation capacity
f normal human lungs can provide a substantial buffer betweenearly damage and later clinically signiﬁcant disease with impair-
ment [73]. As a result, many forms of bronchiolitis are described as
indolent and unlikely to have fatal consequences; however, some
acute bronchiolitis entities can result in more severe and deadly
conditions, and chronic bronchiolitis can also evolve to BO disease
[73].
BO disease is a rare disease entity that speciﬁcally involves
irreversible obstructive ﬁbrosis of the small airways (bronchioles)
[50,52,73]. BO disease is characterized by extensive ﬁbrosis of the
respiratory bronchioles that limits air exhalation or ventilation
leading to reduced oxygenation especially with physical exertion
[31,52,73]. The clinical course following inhalation of irritant gases
known to cause BO disease initially involves acute respiratory
distress associated with lung edema that occurs within days of suf-
ﬁciently high exposure [50]. Onset of respiratory symptoms occurs
without an appreciable delay, i.e., the latency between causal expo-
sure and evidence of disease onset is relatively immediate [83].
However, BO disease may  also demonstrate a longer latency due to
other causes, such as when it develops as an exaggerated healing
response following acute or chronic bronchiolitis [52,73] or during
the late stages of hypersensitive pneumonitis [50,73]. Addition-
ally, bronchiectasis, chronic emphysema, and chronic bronchitis
can progress to BO disease [50,73]; thus determination of cause
and effect can be very complex. In acute or chronically developed
BO disease, clinically signiﬁcant pulmonary function deﬁcits and
conﬁrmed histology can be apparent. The diagnostic criteria for BO
shown in Table 1 have been reviewed by several researchers with
essentially concordant views [50,52,73,92,96,97].
The diagnostic criteria used for BO disease overlap with the
manifestations of other lung disorders having variable etiologies.
For example, mosaic lung attenuation has also been observed in
asthma and emphysema [52,92]. There are also similarities with
clinical presentation and pulmonary function testing between BO
disease and other obstructive lung diseases [52]. In addition to
a detailed medical and exposure history, a lung biopsy is often
essential to distinguish BO disease from various other diseases
potentially affecting the bronchioles [73].
Laohaburanakit and colleagues [52] noted that:
“In the case of BO that is not related to transplantation, the diagno-
sis is much more challenging and requires a high index of suspicion. The
clinical presentation, as well as pulmonary function testing character-
istics of BO, are non-speciﬁc and resemble other obstructive diseases
such as asthma and COPD [chronic bronchitis and emphysema]. [· · ·]
Surgical lung biopsy, either by open lung biopsy or video-assisted tho-
racoscopic surgery (VATS) is usually required when BO occurs outside
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f transplantation and the diagnosis cannot be made by transbronchial
iopsy.”
Chan and Allen [12] noted that:
“Lung biopsy is the only way to deﬁnitively diagnose BO, whether
r not it is related to organ transplantation.”
“Constrictive bronchiolitis” is recognized as a synonymous term
or describing BO lesions. However, some investigators have broad-
ned the deﬁnition of constrictive bronchiolitis to include indolent,
ubclinical, and/or relatively isolated bronchiolar lesions with-
ut ﬁxed airway obstruction and with no appreciable impact on
lood oxygenation or other objective clinical indicators of disease
32,48,47]. Furthermore, cases of possible subclinical constrictive
ronchiolitis have not been conﬁrmed by lung biopsy [33]. This
roadened deﬁnition increases the difﬁculty in establishing cause
nd effect relationships because it encompasses other obstructive
ronchiolitis entities, with varied risk factors, pathologies, and clin-
cal severities.
For example, a clinical disease entity that often results in
ixed obstructive-restrictive spirometry ﬁndings can be caused
y long-term, heavy cigarette smoking: respiratory bronchiolitis-
ssociated interstitial lung disease [50,84,96]. The less severe
ondition known as respiratory bronchiolitis or “smoker’s bron-
hiolitis” is a common histological ﬁnding in the lungs of smokers
nd ex-smokers [50,84]. Respiratory bronchiolitis among smokers
as subtle histological similarities to BO, with mild peribron-
hiolar ﬁbrosis, but apparently develops more slowly and the
ronchiolar changes typically don’t play a critical role in the ulti-
ate loss of normal lung function due to smoking and associated
mphysema [50,73]. The interstitial lung disease component is
haracterized by the presence of mild ﬁbrosis and pigmented intra-
uminal macrophages (“smoker’s macrophages”) within the ﬁrst
nd second-order respiratory bronchioles [50]. Most instances of
his disease are associated with mild clinical symptoms, mild to
oderate obstructive-restrictive patterns on pulmonary function
ests, and ground-glass attenuation on high resolution computed
omography lung scans (HRCT) [84]. This disease may  occur in con-
unction with emphysema in persons with over 30 pack-years of
igarette smoking, typically in their fourth or ﬁfth decade of life
50].
Another disease that could be mistaken for BO disease if the
roader deﬁnition of constrictive bronchiolitis was accepted is
ronchiolitis obliterans organizing pneumonia or BOOP [96]. BOOP
s also called cryptogenic organizing pneumomia and is considered
rimarily an interstitial lung disorder, in contrast to BO disease
hich is primarily a small airway disorder [17,28,50]. BOOP has
een historically confused with BO due to its nomenclature; how-
ver, it is a clinical disease entity that is distinctly different from BO
isease in terms of its pathology, diagnostic criteria, and associated
isk factors [17,28,52,73,85,96]. BOOP may  exhibit features of ‘inﬁl-
rative bronchiolitis’, describing serious acute inﬁltration of the
ronchioles with immune cells typically in response to lung infec-
ions or an autoimmune disease [28,52]. BOOP can lead to ﬁbrotic
olyp lesions that may  obliterate patchy areas of bronchioles, which
nly on biopsy can be distinguished from the concentric ﬁbrotic
esions of the bronchioles seen in BO disease [52]. BOOP is most
ften a reversible acute condition causing restrictive (not ﬁxed
bstructive) lung changes and requiring antibiotics and corticoste-
oid treatment to resolve [50]. BOOP is not thought to lead to clinical
O disease; however, repeated and/or serious infections can result
n BOOP leading to ﬁbrotic bronchiolar lesions that upon biopsy
ay  resemble patchy occurrence of BO lesions and/or bronchiecta-
is [17,28,85]. Indeed, BO and bronchiectasis lesions are commonly
een in late stages of many chronic lung diseases as explained by
73].
In sum, bronchiolitis diseases include a wide variety of patho-
ogically unique entities, with overlapping histology and clinical Reports 2 (2015) 1463–1472 1465
symptoms. Accurate distinction between diseases is essential for
predicting the clinical severity and progression of the obstructive
symptoms. Furthermore, the etiologies of these various bronchiolar
disorders vary signiﬁcantly, from inhaled irritant gases or cigarette
smoke to infectious diseases and autoimmune diseases [73]. As a
result, failure to establish the correct diagnosis may  lead to incor-
rect conclusions regarding cause and effect. Full consideration of
the criteria and methods for diagnosis, the observed disease pro-
gression, and the patient’s underlying conditions and alternative
exposures is essential for proper diagnosis as well as for cause and
effect determinations regarding BO disease.
2. Risk factors for restrictive and obstructive lung diseases
and bronchiolitis obliterans disease
BO is a multi-factorial disease with critical host and non-
occupational environmental determinants of risk [73]. Generally,
a variety of known or suspected risk factors have been identiﬁed
for restrictive and obstructive lung diseases that may  include BO
lesions, including cigarette smoke, fetal exposures, environmental
exposures, pharmaceutical treatments, and infectious and autoim-
mune diseases. Since BO lesions are associated with a variety of
chronic lung diseases, it is important to understand the differences
in clinical features and risk factors between BO disease and other
lung diseases.
The number of risk factors for obstructive lung disease can
hamper epidemiology studies seeking to identify causative agents.
Balmes [8] noted that exposures potentially causing chronic
obstructive pulmonary disease (COPD) in the workplace have been
difﬁcult to deﬁne clearly in epidemiological studies for the follow-
ing reasons:
“First, COPD is multi-factorial in cause with critical (and mostly
unknown) host, as well as non-occupational environmental determi-
nants, of risk. Second, unlike workers with pneumoconiosis, individuals
with COPD caused by occupational exposures cannot be distinguished
from those with disease resulting from other causes. Third, many work-
ers with COPD have concurrent exposure to cigarette smoke (direct
or second-hand) and workplace irritants. Fourth, exposed workers
at baseline usually have better overall health and higher ventilatory
function than the general population, the so-called healthy worker
effect. Fifth, workforce studies are often limited to a survivor popu-
lation because of the inability to assess or follow workers who leave
their jobs, thereby underestimating the chronic effects of occupational
exposures.”
There is a broad range of agents that have been reported as
known or suspected causes of either chronic bronchitis, bronchi-
olitis, BO disease, and/or similar small airways disease in humans,
as illustrated for environmental exposures and disease states in
Table 2 [3,5,8,10,12,52,56,68,73,79,85,87,97,106,110]. With respect
to pharmaceutical or iatrogenic associations (see Table 3), most
cases of BO disease are linked to heart/lung and bone marrow trans-
plants and autoimmune connective tissue disease risk factors listed
in Table 3, with the infectious agents more prominently affecting
young children [12,17,79]. Additionally, many drugs used to treat
BOOP and/or underlying diseases that may  cause BOOP have been
identiﬁed as possible risk factors (perhaps mistakenly) for BO dis-
ease in some individuals [5,10,29,106]. As noted earlier, repeated
serious infections like BOOP may lead to BO lesions but not clinically
deﬁned BO disease [17,28].
2.1. Cigarette smokeThe predominant cause of chronic bronchitis, emphysema,
respiratory bronchiolitis, and respiratory bronchiolitis-associated
interstitial lung disease throughout the world is cigarette smok-
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Table  2
Environmental exposures and disease states associated with bronchiolitis and/or
bronchiolitis obliterans disease.
Irritant gases, fumes or dusts:
Ammonia, chlorine, hydrogen sulﬁde, mustard gas, smoke inhalation, sulfur
dioxide, oxides of nitrogen (NO, NO2, N2O4), phosgene, di-isocyanates,
volatile ﬂavoring agents, hot gases, ﬂy ash, zinc chloride, metals (osmium,
vanadium), metal oxide fumes (welding fumes), organic dusts (cotton, grain,
wood), mineral dusts (coal, vitreous ﬁbers, oil mist, Portland cement, silica,
silicates), smoke (engine exhaust, tobacco smoke, ﬁre smoke), overheated
cooking oil fumes, spice dust.
Ingested toxins: Sauropus androgynus
Drug interactions: cocaine
Infectious and autoimmune diseases:
Chronic hypersensitivity pneumonitis
Childhood infections: (measles, respiratory syncytial virus, inﬂuenza,
parainﬂuenza, adenovirus, mycoplasma, mycobacteria, pertussis)
Infections per se: (Herpes simplex virus, human immunodeﬁciency virus-1,
Cytomegalovirus,  Rubeola, Parainﬂuenza type 3, Adenoviruses, Mycoplasma
pneumoniae,  Klebsiella, spp., Haemophilus inﬂuenzae,  Bordatella pertussis,
Mycobacterium chelonae, Nocardia asteroides, Cryptococcus neoformans,
Pneumocystis carinii)
Graft vs. host disease: (bone marrow, lung or heart-lung transplants)
Auto-immune connective tissue disorders: (rheumatoid arthritis, eosinophilic
fascitis; polymyositis, cystic ﬁbrosis with chronic infections, inﬂammatory
bowel disease, Swyer-James syndrome, Sjogren’s syndrome, Systemic lupus
erythematosus)
Table 3
Pharmaceutical and iatrogenic factors associated with bronchiolitis and/or bronchi-
olitis obliterans disease.
Antimicrobials:
Minocycline, nitrofurantoin, cephalosporin, amphotericin-B, daptomycin,
abacavir, tiopronin, lomustine, sulfasalazine, penicillamine
Anticancer agents:
Bleomycin, busulphan, doxorubicin, methotrexate, mitomycin-c,
chlorambucil, cyclophosphamide, dihydroergocryptine, dihydroergotamine,
hexamethonium, cytarabine ocfosfate, rituximab, oxaliplatin,
aurothiopropanosulfonate, radiation therapy, Sauropus androgynus
Cardiovascular agents:
Amiodarone, acebutolol, pravastatin, simvastin, sotalol, ticlopidine,
mecamylamine
Anti-inﬂammatory or immunosuppressive agents:
Gold, sulfasalazine, methotrexate, aurothiopropanosulfonate, inﬂiximab
mesalamine/mesalazine, bucillamine, D-penicillamine, azathioprine,
6-mercaptopurine, tacrolimus, sirolimus, everolimus
Anticonvulsants:
Carbamazepine, phenytoin
Miscellaneous drugs:
Interferons alpha, beta and gamma, hexamethonium, L-tryptophan, FK 506,
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observed for these patients regardless of whether or not they exhib-barbiturates, nilutamide, tacrolimus, topolean, and free-base cocaine use,
sulindac, ticlopidine, heroin, ﬂuvastatin, venlafaxine, risedronate, lomustine
ng [84]. As noted above, mild ﬁbrotic peribronchiolar changes
re associated with respiratory bronchiolitis and respiratory
ronchiolitis-associated interstitial lung disease [50]. Furthermore,
hronic bronchitis and emphysema can progress to concurrently
nvolve BO lesions but are not clinically deﬁned as BO disease
50,52].
.2. Fetal exposures
Maternal drug intake as well as premature birth (and associated
yaline membrane disease or bronchopulmonary dysplasia) may
ave substantial detrimental long-term effects on the lung [91,99].
ang [98] noted that fetal exposure to nicotine from maternal
moking produces small airway changes in experimental animals
nd human fetuses that may  affect bronchiolar function and disease
isks in adulthood [13,64,100]. Thus, in some individuals a substan-
ial portion of the cumulative lung damage that results in clinical
bstructive lung disease during adulthood may  date back to expo-
ures or diseases affecting the fetus or newborn. Such risk factors Reports 2 (2015) 1463–1472
may  be unknown to the affected individual when onset of lung
disease occurs decades later.
2.3. Possible role of chronic sinusitis in obstructive lung diseases
Irritant gases, particularly those with high water solubility, may
be capable of causing chronic sinusitis that can lead to obstructive
lung disease including small airways disease, bronchiolitis oblit-
erans lesions, and bronchiectasis [51]. Chronic sinusitis involves
the persistent occurrence of abnormal sinus drainage and associ-
ated swelling, pain, and associated problems for 12 weeks or more;
it is usually associated with allergic rhinitis and changes in sinus
and lung responses to allergens with increasing age [78]. In most
cases, this condition is associated with chronic inﬂammation of
nasal/sinus tissues related to abnormal increases in certain immune
cells (eosinophils) that trigger swelling and edema in a manner
that prevents normal drainage [11,14,78]. The chronic eosinophil-
related inﬂammatory process is commonly related either to an
allergic response (e.g., dust mite allergy of the respiratory tract),
to abnormal immune responses (which may  relate to nutritional,
genetic, or age- and immune disease-related factors), or possibly
to an anatomical abnormality of the nasal sinuses (e.g., congenital
deviated nasal septum that can readily exacerbate sinus drainage
problems).
Chronic sinusitis is extremely common and its prevalence
increases with age, particularly starting around the ﬁfth decade
[54]; it is reported to affect more than 30 million people in the
United States population [20], or about 1 in every 7 American adults
[11]. Chronic sinusitis is highly prevalent in adults with severe
asthma [105] and in persons who  develop bronchiectasis and asso-
ciated permanent obstructive lung changes [36].
Allergy testing is important because it is often the case that res-
piratory allergens can exacerbate chronic sinusitis and more severe
cases (of allergic rhinitis) are linked to the occurrence of adult-onset
asthma. For example, Magnan and colleagues [55] reported that
55% of asthmatics have allergic rhinitis, and that more severe res-
piratory allergies correlate with greater asthma severity and worse
asthma control. Indeed, persistent allergic rhinitis is considered a
strong risk factor for adult-onset asthma and it has been reported
that up to 80% of patients with persistent allergic rhinitis have clin-
ical asthma or a related condition called bronchial hyperreactivity
[15,16,90]. Thus, adults who develop severe and persistent aller-
gic rhinitis are at increased risk of developing chronic sinusitis and
related asthma and/or bronchial hyperreactivity that may be a risk
factor for permanent obstructive changes [55].
More severe cases of chronic sinusitis can increase the risk of
permanent obstructive lung changes and speciﬁcally small airways
disease with end stage changes that may  also include bronchiec-
tasis. Ragab and colleagues [80] reported that 60% of patients with
chronic sinusitis had lower airway (bronchi, bronchioles, and alve-
oli) disease including 24% with clinical asthma and 36% with small
airways disease (i.e., bronchiolar disease) as indicated by reduced
spirometry measurements of forced expiratory ﬂow at 25–75%
(FEF25–75). Lamblin and colleagues [51] studied 46 patients hav-
ing persistent chronic sinusitis with nasal polyps and reported that
non-reversible obstructive changes were observed on spirometry
testing of most cases who  were followed over a 4-year period.
Greater obstructive changes were observed in 28 of the 46 patients
who were considered to be ‘non-responders’ to aerosol steroid
therapy used to treat the chronic sinusitis, and signiﬁcant declines
in spirometry parameters (FEV1, FEV/FVC ratio, and FEF25–75) wereited clinical asthma [51]. Guilemany and colleagues [36] reported
that chronic sinusitis with nasal polyps was  present in 25% of
patients with clinical bronchiectasis, also an irreversible obstruc-
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not cause bronchiolar ﬁbrosis [4,9,46,57,60,83,95]. One must also
consider that reported associations between non-traumatic sul-
fur mustard gas exposures and delayed BO disease have not been
supported by biopsy conﬁrmation [33], and hence other possible
Table 5B.D. Kerger, M.J. Fedoruk / Toxi
ive lung lesion. Thus, chronic sinusitis may  be a risk factor for ﬁxed
bstructive lung disease.
In sum, there are many chronic lung diseases that in later stages
an result in the occurrence of BO lesions that often have limited
linical signiﬁcance and hence are not considered to represent BO
isease. The wide variety of risk factors and commonality of COPD
an make the determination of cause and effect relationships for
bstruction from BO lesions difﬁcult. Resolution of this problem is
ssisted by more speciﬁc deﬁnition of BO disease as widespread
oncentric bronchiolar ﬁbrosis causing clinically signiﬁcant respi-
atory impairment such as reductions in lung function and/or blood
xygenation due to unequivocal bronchiolar obstruction. This deﬁ-
ition of BO disease generally avoids more equivocal or subclinical
ases and is inferred in our use of this terminology going forward.
. Time course and pathology associated with inhaled
rritant gases known to cause bronchiolitis obliterans
isease
Additional insights regarding the potential causes of BO dis-
ase can be gleaned from the magnitude of exposure and timing
etween the suspected causal exposure and the onset of airway
njury responses. Schacter and colleagues [87] noted,
“Historically, airway injury has been one of the most common occu-
ational hazards. The difﬁculty facing the physician who  suspects an
ccupational airway disease is to sort out whether the illness is truly
elated to workplace exposure.
Bronchiolitis obliterans is a well-characterized inﬂammatory
esponse of the terminal airways. Inﬂammation results from a usu-
lly massive exposure to irritant gases that penetrate to the lower
irways (for example, nitrogen dioxide). Characteristically, after initial,
elatively mild symptoms of mucous membrane irritation, pulmonary
dema follows in an explosive manner. If the patient survives, bron-
hiolitis obliterans may  develop. Frequently, a persistent, chronic
bstructive lung disease ensues”.
Schacter and colleagues [87] indicated that pulmonary edema
nd acute respiratory distress from “massive” exposures that may
ead to BO disease are uniformly observed within days. This is
n agreement with other reviewers on the sequelae of massive
nhaled irritant exposures [30,31,52,56,73,103]. In such instances of
cute respiratory distress from massive inhaled irritant exposure,
o Pico [30] noted that the most common outcomes may  include
eactive airways dysfunction (an asthma-like condition) or com-
lete recovery. BO disease is an uncommon clinical outcome. When
t occurs due to acute inhalation exposures, BO disease develops
uickly with a characteristic clinical course as described in Table 4
30,44,52,81,103,104,107]. Thus, there is a general scientiﬁc con-
ensus that traumatic acute exposures to certain inhaled irritant
ases follow a predictable time course.
As explained earlier, some researchers have adopted a broader
eﬁnition of ‘constrictive bronchiolitis’ and BO disease that
ncludes more indolent forms without obstructive changes or
able 4
ime course of bronchiolitis obliterans disease from acute irritant gas exposures.
Within typically 1–3 days:
Lung edema/chemical pneumonia
Severe shortness of breath
Acute respiratory distress syndrome (ARDS)
Lymphocytic and neutrophilic inﬁltration
Within typically 3 weeks to 3 months (without timely steroid and antibiotic
therapy):
Fixed obstructive lung changes from widespread concentric bronchiolar
ﬁbrosis
Superinfection and bronchiolitis obliterans obstructive pneumonia (BOOP)
Alveolar and upper airway lesions depending on agent and acute dosage Reports 2 (2015) 1463–1472 1467
clinically signiﬁcant symptoms [47,58]. However, such a broad def-
inition of BO disease provides little insight on causal elements
and timing of disease onset, and such diagnoses are more likely
to be confounded by idiopathic or secondary bronchiolitis condi-
tions such as concurrent and/or repeated infections, underlying
autoimmune or immune deﬁciency diseases, or other risk factors
[73,98]. Similarly, the timing of onset for many forms of ﬁxed air-
way obstruction is often dependent on the cumulative damage to
the lungs that occurs as an end result of a variety of chronic expo-
sures or disease states [98,101], e.g., chemical, physical, infectious,
and other insults that may  have occurred from fetal development or
early childhood through the point where symptoms are sufﬁciently
severe to lead to a doctor visit and diagnosis. Because the early signs
of ﬁxed airway obstruction—easy fatigue and shortness of breath
on exertion—can be explained by common factors such as decon-
ditioning, viral infections, and even depression, an early diagnosis
is rare in the absence of spirometry screening or onset following
a severe respiratory infection like pneumonia [52,96]. Moreover,
the rare clinical entity that most researchers deﬁne as BO disease is
characterized by conﬁrmed ﬁbrotic pathology of the bronchioles in
the absence of other potentially causal disease processes [12,52,73].
The range of pathology ﬁndings that can be associated with var-
ied doses of irritant gases reaching the bronchiolar epithelium is
summarized in Table 5, ranging from normal healing or lung epithe-
lium remodeling at low doses to severe bronchiolitis obliterans
disease and possibly bronchiectasis at high doses. The potential for
non-traumatic inhaled irritant gas exposures (i.e., those not asso-
ciated with an acute respiratory distress syndrome within hours to
days after the causal exposure) to cause BO disease years or decades
later has also been discussed in recent literature pertaining to sul-
fur mustard gas exposures; associated clinical presentations range
from unimpaired to severe impairment with respect to shortness of
breath and lowered blood oxygenation [32,33,86,102]. The occur-
rence of BO lesions is not a deﬁnitive disease state unless there
are clinically important ﬁxed airway obstruction and/or impaired
blood oxygenation related to bronchiolar ﬁbrosis [12,52,73].
It is scientiﬁcally tenuous to attribute non-traumatic inhaled
irritant gas exposures as a primary cause of BO disease. For exam-
ple, the threshold-dependent mechanism of toxic action leading to
BO disease from sulfur mustard gas is driven by cytotoxicity, DNA
alkylation, and overwhelming of antioxidant defenses at doses suf-
ﬁcient to denude the respiratory epithelium, while lower doses doCharacteristic pathology ﬁndings of bronchiolitis obliterans disease from acute irri-
tant gas exposures.
Low acute doses (not sufﬁcient to denude bronchiolar epithelium):
With infrequent exposures, e.g., 2 week intervals—Normal healing and
replacement of bronchiolar epithelium
With frequent exposures, e.g., daily—Remodeling of more sensitive cell
types (e.g., clara cells) to less sensitive types
Threshold-dependent responses (doses sufﬁcient to denude bronchiolar
epithelium)
Severe bronchiolar inﬂammatory response
Cytotoxicity with severe basement membrane damage
Severe neutrophilic inﬁltration
DNA-alkylation and stunted healing and remodeling
Possible longer-term responses (without timely steroid and antibiotic
therapy):
Widespread concentric bronchiolar ﬁbrosis
Possible chronic bronchitis (purulent) from repeated infection
Possible bronchiectasis (in addition to concentric ﬁbrosis) from
repeated/chronic infection
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auses of underlying ﬁxed airway obstruction were typically not
uled out. Moreover, the inﬂuence of subsequent chronic infec-
ious disease (e.g., chronic bronchitis and repeated pneumonia
pisodes) or other risk factors for ﬁxed airway obstruction may  pro-
ide more credible explanations for the development of BO disease
ears or decades later in persons not exhibiting an acute respiratory
istress response soon after the causal exposure [93]. Similar con-
iderations may  apply to reports of delayed BO disease and other
bstructive diseases in a group of soldiers exposed to a sulfur plant
re or burn pits during the recent war in Iraq [1,7,44,67].
Chlorine and phosgene are toxic gases that have been used as
hemical weapons to induce rapid lung edema and act as ‘choking
gents;’ they are also known inducers of BO [74]. Most survivors
f high acute exposures to these choking agents have no long-
erm consequences with proper treatment, although exertional
yspnea and increased bronchial resistance may  persist for sev-
ral months to years [21,74,83]. Similar to mustard gas exposures,
he mechanism of toxic action for phosgene-induced BO disease is
riven by extensive cytotoxicity and denuding of the respiratory
pithelium that only occurs with relatively high concentrations
eaching the bronchioles [19,23,24,34,37,39,45,70,88]. The timing
f potential development of BO disease following phosgene expo-
ure is typically within months following traumatic exposures in
umans [22,70] and is more rapid (i.e., typically within days) in
ertain laboratory test species [45,75,77,76]. Also, patients surviv-
ng the lung edema phase after traumatic phosgene exposure who
o not receive preventive antibiotic therapy may  develop “superin-
ective pneumonia” and repeated/chronic infections that can lead
o bronchiectasis and/or BO disease [21]. It has also been noted
hat individuals with pre-existing lung damage may  be at greater
isk of developing BO disease years after traumatic phosgene expo-
ures [22,70]. In such cases of pre-existing lung damage prior to a
raumatic phosgene exposure, it may  be difﬁcult or impossible to
etermine which risk factors were most important in subsequent
evelopment of BO disease.
. Adaptive response to irritants
Phosgene has been used as a research tool to understand the
nﬂuence of adaptation on dose-response relationships for acute
nd chronic lung injury. With respect to ﬁbrotic changes developing
fter traumatic phosgene exposures in animals, there are species-
elated differences in susceptibility (e.g., mice do not develop
brotic bronchiolar changes while rats and dogs develop such
hanges within days to weeks) [24,39,45,77,75,76]. Rats appear to
e about 10-fold more susceptible to phosgene-induced bronchio-
ar ﬁbrosis compared to dogs or humans due to differences in lung
natomy and breathing characteristics [23,77]. In rats, it has been
hown that pretreatment of animals with nontraumatic doses of
hosgene will increase adaptation leading to greater phosgene tol-
rance, i.e., reduced occurrence/severity of lung injury compared
o responses in newly exposed animals [34,39]. Hatch and col-
eagues [39] noted that such lung adaptation/tolerance reactions
rom phosgene pretreatment may  be analagous to ultraviolet light
xposures to human skin, where a series of smaller, nontraumatic
xposures (e.g., inducing suntan but not sunburn) can be subse-
uently protective against sunburns that are strongly correlated
ith skin cancer risk. In the context of phosgene-induced bronchi-
lar ﬁbrosis in rats, it is the number and timing of exposure events
eading to signiﬁcant cytotoxicity and denuding of the bronchio-
ar epithelium that equates with risk and severity of lung ﬁbrosis;
his is because regular low concentration exposures (e.g., daily or
eekly events not capable of causing denuding of the bronchiolar
pithelium) foster adaptation and greater tolerance to phosgene-
nduced lung injury [34,39]. Reports 2 (2015) 1463–1472
5. Evidence on time course and pathology of
diacetyl-induced lung damage
The likelihood that an inhaled irritant gas will reach the smaller
airways at sufﬁciently high concentrations to cause clinically
important tissue damage is essential with respect to the timing and
localization of BO lesions or BO disease [73,74]. To evaluate this, it
is necessary to understand how the physical/chemical properties
of the suspected causal agent interact with the lungs. For example,
Maier [56] noted,
“The effect of the substance inhaled depends on the physicochemi-
cal properties of the substance, with water-insoluble substances being
more likely to reach the lung and cause acute lung injury. The pH, chem-
ical reactivity, properties of the gas or aerosol, such as particle size and
amount of substance inhaled or ingested, also determine toxicity.”
Similarly, Schacter and colleagues [87] noted that,
“Not all gases that irritate mucous membranes are equally danger-
ous to the airways. For example, formaldehyde is potentially far more
irritating to the mucous membranes of the eyes and nose than are sulfur
dioxide or nitrogen dioxide, yet it has little or no airway effect at usual
occupational levels, although sensitization may occur. Gases such as
formaldehyde, which are highly soluble and are maximally absorbed
in the upper airways, may not reach the lower airways in concentra-
tions high enough to cause damage or irritation. The solubility of the
gas and its ability to reach the lower airway is felt to be an important
factor in promoting airway effects.”
Thus, the more water soluble agents, such as acetaldehyde and
ammonia gases, cause severe irritation of the eyes, nose and throat
concurrent with effects occurring in the lower respiratory tract at
the bronchioles.
Diacetyl vapors are highly water soluble and thus become
absorbed primarily in the mucous of the nasal sinuses, trachea and
bronchi [35]. Like ammonia, diacetyl is irritating to the mucous
membranes of the eyes, nose, and throat at sufﬁciently high concen-
trations and is expected to cause irritation, acute inﬂammation, and
associated avoidance responses in exposed individuals [103]. Thus,
severe eye, nose, and throat irritation would occur at exposures to
these agents that might cause clinically important tissue damage
in the bronchiolar region. Highly water soluble irritants therefore
usually have strong irritant properties that cause workers to avoid
acute high exposures. In contrast, less water-soluble chemicals like
phosgene and nitrogen dioxide have a greater potential for causing
‘insidious’ bronchiolar tissue damage, i.e., in the absence of frank
signs of upper respiratory inﬂammation [21,103].
Diacetyl exhibits good warning properties due to its water sol-
ubility (up to 200 g/L; [61], pungent odor, and acute irritation
effects on the mucous membranes of the eyes, nose and throat [38].
Upper respiratory irritants such as diacetyl and simple aldehydes
(like formaldehyde, acetaldehyde, and acrolein) cause immediate
inﬂammation of the mucous membranes of the eyes, nose, and
throat at sufﬁcient doses which leads to immediate avoidance
responses in workers. Workers involved in jobs with intermittent
exposures to irritant gases can learn how to avoid getting a sting-
ing dose by using breath-holding, body positioning away from the
emission path, and by using personal protective equipment or other
techniques to prevent regular or substantial self-exposures.
Diacetyl is far more water soluble than phosgene [61]. Thus,
while phosgene is capable of reaching the bronchiolar region at
higher concentrations following inhalation [70] diacetyl becomes
absorbed primarily in the nasal passages and bronchi of test ani-
mals. Diacetyl is also rapidly metabolized and eliminated from
the body upon inhalation [35,65] and as a result does not partici-
pate in disease processes occurring months or years after diacetyl
exposure has ceased. Gloede and colleagues [35] developed a phar-
macokinetic model of rat and human respiratory uptake of diacetyl
and reported that mouth-breathing humans under light exercise
cology Reports 2 (2015) 1463–1472 1469
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Table 6
Characteristics of diacetyl chemistry and kinetics that don’t ﬁt with causation of
bronchiolitis obliterans disease at plausible human exposure concentrations.
Relatively high water solubility (200 g/L):
Good irritant warning properties (eye, nose and throat inﬂammation,
sensory irritant)
Implies good potential for learned avoidance for individuals with repeated
exposures
Good tissue distribution for respiratory uptake
Low chance of insidious occurrence at the bronchioles
Rapid metabolism and excretion like a sugar/ketone body:
Accumulation at bronchiolar target tissue unlikely
Not a cumulative or insidious toxicant at the bronchioles
Threshold-type dose-response for epithelial tissue injury:
Poor dose-response correlation in epidemiology studies; marker vs. actual
cause?
‘Textbook’ dose-response relationship for animal inhalation studies of acute
irritants
Rats are 10-fold more sensitive than humans (bronchiolar inﬂammation at
50  + ppm TWA)
Based on rat lung inﬂammation response, human effective dose may start at
500 ppm TWA
Typical workplace exposure concentrations with handling of concentrated
diacetyl: 0.1–3 ppm
Type of pathological responses should be comparable to other irritant gases:
Acute chemical burn to bronchioles seen in animals and humans with
known causes
No bronchiolar ﬁbrosis in diacetyl inhalation studies in animals, unclear in
human studies
Latency to onset of pathological responses should be comparable to other
irritant gases:
Rapid lung edema, ARDS, and bronchiolar ﬁbrosis in animals and humans
with known causes
Latency pattern inconsistent among human BO cases associated with
diacetyl
No apparent mechanistic differences for cytotoxicity compared to other
irritant gases:
Acute chemical burn to the bronchioles; no unique mechanistic factors to
dateB.D. Kerger, M.J. Fedoruk / Toxi
ight develop bronchiolar tissue concentrations 40-fold higher
han those occurring in rats. However, as noted above for phosgene,
he rat model may  be at least 10-fold more sensitive to bronchiolar
njury than dogs or humans due to differences in lung anatomy and
reathing characteristics [23,76].
Consistent with phosgene research, diacetyl did not induce
brotic bronchiolar changes in mice [62] but was capable of pro-
ucing some degree of bronchial and/or bronchiolar inﬂammation
n rats at sufﬁciently high inhalation doses, e.g., time-weighted
verage (TWA) diacetyl concentrations of 50 ppm or higher [71].
ince rats are considered to be at least 10-fold more sensitive
han humans to bronchiolar inﬂammation from phosgene (due to
ung anatomy and breathing physiology [21,76]), the TWA  diacetyl
oncentration capable of causing similar bronchiolar responses in
umans may  be 500 ppm or higher. For context, surveys of food or
avoring workplaces that involve handling of concentrated diacetyl
108,109] typically involve TWA  diacetyl concentrations in the low
pm range, e.g., between 0.1 and 3 ppm. Bronchiolar ﬁbrotic lesions
ave also been reported to result from direct intratracheal instil-
ation of diacetyl [72], although these investigators acknowledged
hat intratracheal instillation is not physiologically relevant human
xposure pathway for diacetyl.
The timing of diacetyl-induced bronchiolar ﬁbrosis follow-
ng intratracheal instillation in rats [72] was comparable to that
bserved for phosgene (i.e., within days). Bronchiolar ﬁbrotic
esions observed in some human cases associated with occupa-
ional diacetyl exposure have reportedly occurred within a span of
 few months following start of exposure, although many suspected
ases reportedly occurred many years after ﬁrst occupational expo-
ure and in workers with relatively low diacetyl exposures [48,47].
ssuming the rat studies on diacetyl intratracheal instillation [72]
nd of 2,3-pentanedione inhalation [63] are relevant to predicting
brotic lung injury in humans, the mechanism of injury leading to
ronchiolar ﬁbrosis proposed by these researchers appears to be
imilar to that reported for phosgene. Speciﬁcally, development of
ronchiolar ﬁbrotic lesions induced by diacetyl in rats is thought to
e driven by extensive cytotoxicity and denuding of the respiratory
pithelium that is observed only at sufﬁciently high concen-
rations [48,47,63,72]. Unfortunately, available animal studies of
iacetyl have not examined the potential for adaptation/tolerance
o occur with regular exposures to lower concentrations, as has
een observed for phosgene-induced lung ﬁbrosis in rats [34,39].
In sum, there are many considerations with respect to the tim-
ng, pathology, and toxicology of diacetyl that do not ﬁt the common
attern observed for better characterized agents like phosgene (see
able 6 ). Continuing research is therefore needed to determine
hether or not diacetyl exposure is the true cause of the observed
lusters of BO disease, or is simply a marker for other workplace
xposure(s) that provide a more coherent scientiﬁc basis for estab-
ishing cause and effect.
. Diacetyl toixokinetics and mechanism
Kerger and colleagues [42] recently examined the inﬂuence
f water solubility, diffusivity, metabolism, and other parame-
ers on application of the Gloede and colleagues [35] respiratory
ract dosimetry model to compare predictions of bronchiolar tis-
ue concentrations of acetaldehyde, acrolein, and diacetyl. Table 7
rovides a summary of the model parameters utilized, includ-
ng kinetics parameters for acetaldehyde and acrolein reported by
sgharian and colleagues [49] and those for diacetyl reported by
loede and colleagues. Substantial differences in water solubility,
artitioning, and metabolism between the three compounds lead
o distinctly different outcomes with respect to an example sce-
ario used by Gloede and colleagues [35] involving prediction ofNo known inter-individual susceptibility factors yet recognized:
No unique susceptibility factors identiﬁed to date
bronchiolar tissue concentrations of diacetyl in mouth-breathing
adults under light exercise conditions. As shown in Table 7,
with an inhaled concentration of 1 ppm for each of these com-
pounds in the model, acetaldehyde had predicted bronchiolar
tissue concentrations nearly 4 orders of magnitude higher than
those predicted for acrolein or diacetyl. This greater relative accu-
mulation of acetaldehyde results from its much slower metabolism
and greater resistance to mass transfer that causes greater depo-
sition in the more distal respiratory epithelial tissues, despite its
high water solubility [42]. If this ﬁnding is validated, then it is
likely that acetaldehyde could be a considerably greater health con-
cern than diacetyl or acrolein with respect to bronchiolar tissue
cytotoxic injury and possible ﬁbrotic disease affecting the small
airways in humans. Since diacetyl may  be a marker for, rather
than the cause of, bronchiolitis obliterans disease in available epi-
demiological studies, it is important to consider such respiratory
dosimetry information pertaining to diacetyl and other chemicals,
like acetaldehyde and 2,3-pentanedione, which are common but-
ter ﬂavoring components used and produced in conjunction with
diacetyl.
Just as tissue partitioning and metabolism can greatly affect
the presumed target organ (bronchiolar) concentrations of irritant
gases, recent ﬁndings by Scott and colleagues [89] point out the
importance of liquid-to-air partitioning in exposure assessment
of diacetyl in various ﬂavoring mixtures. Speciﬁcally, Scott and
colleagues [89] reported on headspace and small chamber stud-
ies showing that diacetyl added to soybean oil (as occurred in
1470 B.D. Kerger, M.J. Fedoruk / Toxicology Reports 2 (2015) 1463–1472
Table  7
Respiratory tract dosimetry model parameters for acetaldehyde, acrolein, and diacetyl and model predictions for human bronchiolar concentrations.
Property Acetaldehyde Acrolein Diacetyl
Diffusivity in air (cm2/s) 0.128 0.105 0.091
Diffusivity in water (cm2/s) 1.35E-05 1.22E-05 4.30E-06
Tissue:air partition coefﬁcient 140 88 572
First  order constant, Kp (1/s) 0.0357 0.05 0.005
Saturable pathway constant, Km (ug/L) 1320 0.5 861
Saturable pathway rate constant, Vmax (ug/m3/s) <1.0E-08 6.1E-07 0.964
Water solubility (g/L) 1000 212 200
Modeled concentration (ppm) in human bronchiolar epithelium with light exercise and 74 0.0077 0.0077
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tmouth-only breathing at 1 ppm inhaled air concentration
osimetry model by Gloede and colleagues [35] for a mouth-breathing human un
olleagues [49] and for diacetyl as reported by Gloede and colleagues [35].
icrowave popcorn factory worker exposures) led to unexpectedly
igh emissions of diacetyl when compared to aqueous or propylene
lycol-water solutions used for adding diacetyl to dairy products
nd candies. They also determined that more dilute mixtures may
mit disproportionately higher diacetyl concentrations (i.e., after
ormalizing to liquid diacetyl content) due to diminishing “like dis-
olves like” attractive forces at lower diacetyl concentrations (e.g.,
n solutions below 0.1%). Thus, diacetyl emission rates and expo-
ures depend on the type of ﬂavoring mixture and/or food to which
t is added. Further research is needed to characterize the degree to
hich this may  affect dosimetry in certain workplaces, e.g., those
tilizing more hydrophobic and/or heated ﬂavoring mixtures [89].
One pathway of possible genetic susceptibility for irritant gas
ung toxicity was evaluated recently by Kerger and colleagues [43].
n this study, diacetyl and three other alpha-diketones were eval-
ated for their capability to cause activation or synergistic effects
n the human Toll-like receptor 4 (TLR-4). Human embryonic kid-
ey cells with either human TLR-4 or mouse TLR-4 were tested, but
here was no evidence of receptor activation or synergistic effects
ith any of the tested diketones. TLR-4 receptor activity in humans
s part of the “inﬂammasome” cascade [66] that can lead to exces-
ive cellular immune responses and lung ﬁbrosis in patients with
ertain autoimmune diseases like Crohn’s disease, ulcerative colitis,
nd rheumatoid arthritis [5,18]. Possible connection to TLR-4 recep-
or activity was consistent with the observed time course studies of
eutrophilic inﬁltration and bronchiolar ﬁbrotic changes that fol-
owed diacetyl-induced denuding of the epithelium and disruption
f the basement membrane in studies of intratracheal instillation
72]. Similar ﬁndings were reported for 2,3-pentanedione inhala-
ion [63] in rats. Kerger and colleagues [43] showed that the human
LR-4 receptor does not appear to be involved in diacetyl or 2,3-
entanedione toxicity.
Other investigators have argued that alternative mechanisms
ight exist to explain potential inter-individual differences in
uman responses to diacetyl inhalation. For example, Hubbs and
olleagues [41] argued that diacetyl may  have biological interac-
ions parallel to methyl glyoxal which is thought to play a key role in
therosclerosis in diabetes. Hubbs and colleagues [41] also reported
hat diacetyl may  damage olfactory nerves in the nasal sinuses of
ice. Larsen and colleagues [53] analyzed available rodent study
ata suggesting that diacetyl is a sensory irritant and that sustained
uman exposures over 20 ppm may  cause sensory irritation. Mor-
an and colleagues [63] suggested that diacetyl may  cause injury
o the airway epithelium by alteration of cellular proteins con-
aining arginine, and considered that hapten formation might act
s a susceptibility factor for causing BO disease in humans [59].
lso, Egilman and colleagues [26,27] considered the possibility that
iacetyl and toluene di-isocyanate may  share the same chemical
eaction mechanism based on analysis of molecular orbital ener-
ies, and considered the hapten hypothesis as an explanation for
espiratory bronchiolitis interstitial lung disease possibly related
o diacetyl in chronic cigarette smokers. Dworak and colleaguesht exercise. Parameters for acrolein and acetaldehyde reported by Asgharian and
[25] conducted molecular orbital energies analysis of diacetyl and
toluene di-isocyanate and concluded that diacetyl is unlikely to
have signiﬁcant respiratory sensitization potential. Dermal sen-
sitization from diacetyl has been demonstrated in mice [6,82],
but there is no known connection between dermal sensitization
and pulmonary disease. In sum, these studies to date have failed
to identify strong, speciﬁc and coherent alternative mechanistic
considerations that advance the understanding of diacetyl-related
respiratory effects at relevant exposure concentrations in humans.
Regardless of the mechanism leading to cytotoxicity, the bronchio-
lar ﬁbrosis is triggered by sufﬁcient acute insult causing denuding
of the epithelium down to the basement membrane followed by
neutrophil inﬁltration and ﬁbrotic tissue replacement of the bron-
chiolar epithelium [63].
In summary, diacetyl has been demonstrated to have certain
physical/chemical and kinetics-related characteristics (see Table 6)
that help to explain why the animal inhalation toxicology studies
to date have failed to demonstrate bronchiolar ﬁbrosis at plausible
human exposure concentrations. Each of these factors, in addition
to workplace exposure assessment differences, must be taken into
careful consideration when assessing whether or not a suspected
chemical like diacetyl is a cause of bronchiolitis obliterans disease
in humans.
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